US Dollar vs MXN

Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

Regístrate

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XLRN

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
23/01/2020	15:15	Business Wire	Acceleron Announces Change to Executive Management Team	NASDAQ:XLRN	Acceleron Pharma Inc
09/01/2020	15:36	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XLRN	Acceleron Pharma Inc
09/01/2020	05:59	Business Wire	New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial	NASDAQ:XLRN	Acceleron Pharma Inc
06/01/2020	06:00	Business Wire	Acceleron to Participate in the 38th Annual J.P. Morgan Healthcare Conference	NASDAQ:XLRN	Acceleron Pharma Inc
30/12/2019	06:30	Business Wire	Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement	NASDAQ:XLRN	Acceleron Pharma Inc
17/12/2019	17:20	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:XLRN	Acceleron Pharma Inc
13/12/2019	15:35	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XLRN	Acceleron Pharma Inc
09/12/2019	15:30	Business Wire	Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of...	NASDAQ:XLRN	Acceleron Pharma Inc
09/12/2019	06:30	Business Wire	Acceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and Development	NASDAQ:XLRN	Acceleron Pharma Inc
06/12/2019	11:45	Dow Jones News	Bristol-Myers, Acceleron: FDA Drops Planned Panel Review of Reblozyl	NASDAQ:XLRN	Acceleron Pharma Inc
06/12/2019	11:05	Business Wire	Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)	NASDAQ:XLRN	Acceleron Pharma Inc
06/12/2019	07:00	Business Wire	Acceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of Directors	NASDAQ:XLRN	Acceleron Pharma Inc
04/12/2019	15:01	Business Wire	Acceleron Named a “Most Honored” Company in Institutional Investor 2020 “All-America Executive Team” Rankings	NASDAQ:XLRN	Acceleron Pharma Inc
03/12/2019	07:35	Dow Jones News	Bristol-Myers, Acceleron: FDA Panel to Review Reblozyl in Myelodysplastic Syndromes	NASDAQ:XLRN	Acceleron Pharma Inc
03/12/2019	06:38	Business Wire	Bristol-Myers Squibb & Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in...	NASDAQ:XLRN	Acceleron Pharma Inc
02/12/2019	06:00	Business Wire	Acceleron to Host Conference Call and Webcast to Review Data Presented at the 61st American Society of Hematology Annual Meet...	NASDAQ:XLRN	Acceleron Pharma Inc
12/11/2019	09:16	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:XLRN	Acceleron Pharma Inc
08/11/2019	12:30	Dow Jones News	Acceleron Pharma Shares Gain Ground After FDA Approves Reblozyl	NASDAQ:XLRN	Acceleron Pharma Inc
08/11/2019	12:20	Dow Jones News	FDA Approves Celgene's and Acceleron's Reblozyl to Treat Rare Blood Disorder	NASDAQ:XLRN	Acceleron Pharma Inc
08/11/2019	11:33	Business Wire	FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular R...	NASDAQ:XLRN	Acceleron Pharma Inc
06/11/2019	08:05	Business Wire	Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual Meeting	NASDAQ:XLRN	Acceleron Pharma Inc
06/11/2019	06:59	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:XLRN	Acceleron Pharma Inc
06/11/2019	06:53	Business Wire	Acceleron Reports Third Quarter 2019 Operating and Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
29/10/2019	06:00	Business Wire	Acceleron to Webcast Third Quarter 2019 Operating and Financial Results on November 6, 2019	NASDAQ:XLRN	Acceleron Pharma Inc
16/09/2019	15:30	Business Wire	Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy	NASDAQ:XLRN	Acceleron Pharma Inc
09/09/2019	06:00	Business Wire	Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension	NASDAQ:XLRN	Acceleron Pharma Inc
05/08/2019	15:05	Business Wire	Acceleron Reports Second Quarter 2019 Operating and Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
24/07/2019	06:00	Business Wire	Acceleron to Webcast Second Quarter 2019 Operating and Financial Results on August 5, 2019	NASDAQ:XLRN	Acceleron Pharma Inc
05/07/2019	08:54	Edgar (US Regulatory)	Confidential Treatment Order (ct Order)	NASDAQ:XLRN	Acceleron Pharma Inc
26/06/2019	06:35	Business Wire	Acceleron Completes Target Enrollment in the PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension	NASDAQ:XLRN	Acceleron Pharma Inc

Showing the most relevant articles for your search:NASDAQ:XLRN

<< Anterior 1 2 3 4 5 6 7 8 9 10 11 Próxima >

BNP Paribas (QX)

Financial Select Sector

American Express

Verizon Communications

Health Care Select Sector

Euro vs US Dollar

Gold vs US Dollar

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones